Literature DB >> 19404247

The global portfolio of new antimalarial medicines under development.

P Olliaro1, T N C Wells.   

Abstract

With the elimination of malaria now considered a realistic goal, it would be useful for scientists and policy makers to have an inventory of the arsenal of antimalarials, current and prospective, that could help make this goal a reality. In order to provide an overview of antimalarial projects in recent clinical development, we review here the global portfolio of antimalarial drugs in clinical phases of development complemented by projects in the preclinical and early discovery phases. The portfolio is discussed in terms of the novelty of the new molecules and their potential health impact in terms of addressing the requirements for the control and eventual eradication of malaria.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19404247     DOI： 10.1038/clpt.2009.51

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  59 in total

1.  Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.

Authors:  Ramesh Gujjar; Farah El Mazouni; Karen L White; John White; Sharon Creason; David M Shackleford; Xiaoyi Deng; William N Charman; Ian Bathurst; Jeremy Burrows; David M Floyd; David Matthews; Frederick S Buckner; Susan A Charman; Margaret A Phillips; Pradipsinh K Rathod
Journal:  J Med Chem       Date:  2011-05-12       Impact factor: 7.446

Review 2.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

Review 3.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

4.  Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties.

Authors:  Jérôme Molette; Julie Routier; Nada Abla; Dominique Besson; Agnes Bombrun; Reto Brun; Howard Burt; Katrin Georgi; Marcel Kaiser; Solomon Nwaka; Mathilde Muzerelle; Alexander Scheer
Journal:  ACS Med Chem Lett       Date:  2013-09-22       Impact factor: 4.345

5.  Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.

Authors:  Yongyuth Yuthavong; Bongkoch Tarnchompoo; Tirayut Vilaivan; Penchit Chitnumsub; Sumalee Kamchonwongpaisan; Susan A Charman; Danielle N McLennan; Karen L White; Livia Vivas; Emily Bongard; Chawanee Thongphanchang; Supannee Taweechai; Jarunee Vanichtanankul; Roonglawan Rattanajak; Uthai Arwon; Pascal Fantauzzi; Jirundon Yuvaniyama; William N Charman; David Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

Review 6.  Antimalarial drug discovery - approaches and progress towards new medicines.

Authors:  Erika L Flannery; Arnab K Chatterjee; Elizabeth A Winzeler
Journal:  Nat Rev Microbiol       Date:  2013-11-11       Impact factor: 60.633

Review 7.  New medicines to improve control and contribute to the eradication of malaria.

Authors:  Timothy N C Wells; Pedro L Alonso; Winston E Gutteridge
Journal:  Nat Rev Drug Discov       Date:  2009-10-16       Impact factor: 84.694

8.  Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Authors:  Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh
Journal:  J Infect Dis       Date:  2013-02-27       Impact factor: 5.226

9.  Agglomerated oral dosage forms of artemisinin/β-cyclodextrin spray-dried primary microparticles showing increased dissolution rate and bioavailability.

Authors:  Anna Giulia Balducci; Enrico Magosso; Gaia Colombo; Fabio Sonvico; Nurzalina Abdul Karim Khan; Kah Hay Yuen; Ruggero Bettini; Paolo Colombo; Alessandra Rossi
Journal:  AAPS PharmSciTech       Date:  2013-05-24       Impact factor: 3.246

10.  Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Stephan Ehrhardt; Christian G Meyer
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.